相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: A report from the BINGO study
Yuichi Ishikawa et al.
CANCER SCIENCE (2010)
Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma
Katerina Micova et al.
CLINICA CHIMICA ACTA (2010)
Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response
Edgar Faber et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders
N. Singh et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group
Mari Sakai et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia
J. E. Cortes et al.
LEUKEMIA (2009)
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels
Donna L. Forrest et al.
LEUKEMIA RESEARCH (2009)
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study
Richard A. Larson et al.
BLOOD (2008)
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Stephane Picard et al.
BLOOD (2007)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing
Edgar Faber et al.
LEUKEMIA & LYMPHOMA (2006)
分享论文
